Development and serology based efficacy assessment of a trivalent foot-and-mouth disease vaccine

Amin, Md. Al; Ali, Md. Ramjan; Islam, M. Rafiul; Alam, Arshad; Shill, Dipok Kumer; Rahman, M; Siddique, Mohammad Anwar; Sultana, Munawar; Hossain, M. Anwar

doi:10.1016/j.vaccine.2020.05.079

Cited by 9 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The neutralizing efficiency of anti-B3 sera indicated that the phylogenetically related strain BAN/DH/Sa-310/2017 was inhibited by anti-B3 sera in VN tests, except for BAN/GA/Sa-197/2013 serotype-A strain. The amino acid changes within the BC loop of this strain rendered the serological insufficiency of both recombinant B3 antigen and inactivated vaccine, also reported by Al Amin et al [18,20]. Although, the GH-loop and C-terminal both B-cell epitopes of BAN/GA/Sa-197/2013 were incorporated in the B3 construct, sufficient antibodies were not developed to confer protection.…”

Section: Antigenic Stability and Protective Immunogenicity Developed By B1 And B3mentioning

confidence: 55%

“…One strain BAN/GA/Sa-197/2013 was neutralized neither by the inactivated monovalent type-A vaccine (positive control) nor by the B3 antigen (Figure 4F). Importantly, the chimeric vaccine (B3) showed significantly (p < 0.001) higher antibody response than the PC group against FMDV strain BAN/GA/sa-197/2013, that previously reported to be mismatched with the developed inactivated vaccine formulated with BAN/CH/Sa-304/2016 [18,20]. Variance of antibody level between other groups of vaccination doses has been illustrated in figure-5.…”

Section: Serum Neutralization Efficiency Of B1 and B3 Developed In The Guinea Pig Modelsmentioning

confidence: 84%

“…Recently, Al Amin et al reported the development of trivalent inactivated FMD vaccine composed of newly emerged global strains of each serotype [20][21][22][23]. Several limitations of inactivated whole virus vaccine pose potential threats towards its acceptability.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A

Akter¹,

Rahman²,

Islam³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Artificially designed, chimeric peptide-based recombinant vaccines are novel approaches to combat the phylogenetically diverse Foot and Mouth Disease (FMD) Virus (FMDV) strains. Among seven distinct serotypes, only serotype O and A are dominantly circulating in Bangladesh and neighbouring countries of Asia, where transboundary transmission, recurrent outbreaks and emergence of novel lineages FMDV are highly prevalent. The objective of this study was to develop multi-epitope recombinant peptides, procuring immunogenicity against circulating diverse subtypes of FMDV serotype O and A. Two chimeric peptides, named B1 (41.0 kDa) and B3 (39.3 kDa), have been designed to incorporate potential B-cell and T-cell epitopes selected from multiple FMDV strains, including previously reported and newly emerged sub-lineages. After expression, characterization and immunization of guineapigs with considerable antigen load of B1 and B3 followed by the serological assays revealed the significant protective immunogenicity, developed from the higher (100 µg) doses of both antigens, against most of the currently prevalent serotype O and A strains of FMDV. The efficient expression, antigenic stability, and multivalent immunogenic potency of the chimeric peptides strongly indicate their credibility as novel vaccine candidates for FMDV serotypes O and A circulating in Bangladesh and surrounding territories.

show abstract

Section: Antigenic Stability and Protective Immunogenicity Developed By B1 And B3mentioning

confidence: 55%

Section: Serum Neutralization Efficiency Of B1 and B3 Developed In The Guinea Pig Modelsmentioning

confidence: 84%

See 1 more Smart Citation

Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A

Akter¹,

Rahman²,

Islam³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…S7 ). Comparative mutational analyses were performed to assess the VP1 protein heterogeneity of the MYMBD21 isolates with the currently available vaccine strain, O/India/R2/75 and recently developed local vaccine strain BAN/TA/Dh-301/2016 24 . Between MYMBD21 and O/India/R2/75, 6 out 11 mutations (D138E, G139S, S140H, V141A, N143S, I144V) were found in the G-H loop and a single mutation (N197S) was found in C-terminal site.…”

Section: Resultsmentioning

confidence: 99%

Emergence of a novel sublineage, MYMBD21 under SA-2018 lineage of Foot-and-Mouth Disease Virus serotype O in Bangladesh

Hossain,

Anjume,

Alam

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

Foot-and-Mouth Disease (FMD) hinders the growth of the livestock industry in endemic countries like Bangladesh. The management and prevention of FMD are severely impacted by the high mutation rate and subsequent frequent generation of newer genotypes of the causative agent, Foot-and-Mouth Disease Virus (FMDV). The current study was conducted in nine districts of Bangladesh during 2019–21 to characterize the circulating FMDV strains based on the VP1 sequence analysis, the major antigenic recognition site providing serotype specificity and high variability of FMDV. This study detected the first emergence of the SA-2018 lineage in Bangladesh along with the predominance of Ind-2001e (or Ind-2001BD1) sublineage of ME-SA topotype under serotype O during 2019–21. The mutational spectrum, evolutionary divergence analysis and multidimensional plotting confirmed the isolates collected from Mymensingh districts, designated as MYMBD21 as a novel sublineage under the SA-2018 lineage. Analysis of the amino acid sequence revealed several changes in the G-H loop, B-C loop and C-terminal region of VP1, revealing a 12–13% divergence from the existing vaccine strains and a 95% VP1 protein homology, with most of the mutations potentially considerable as vaccine escape mutations, evidenced by three-dimensional structural analysis. This is the first report on the emergence of the SA-2018 lineage of ME-SA topotype of FMDV serotype O in Bangladesh, as well as a possible mutational trend towards the emergence of a distinct sublineage under SA-2018 lineage, which calls for in-depth genome-wide analysis and monitoring of the FMD situation in the country to implement a strategic vaccination and effective FMD control program.

show abstract

“…Promising virus vaccine candidates have been prepared using BE and described for use to protect livestock against Foot and Mouth disease in China (Cao et al, 2021), Bangladesh (Al Amin et al, 2020) and India (Sarkar et al, 2017). BE-inactivated vaccine candidate was reported to induce the longest duration of protective IgG levels against transmissible gastroenteritis disease in piglets when compared with vaccine candidates inactivated with formaldehyde and BPL (Zhao et al, 2020).…”

Section: Resultsmentioning

confidence: 99%

Evaluation of a BE-inactivated whole virus preparation using an encephalomyocarditis virus strain that was isolated from fatal infection in orangutans

Tong,

Tan,

Sugrue

2023

Preprint

View full text Add to dashboard Cite

A novel Encephalomyocarditis virus (EMCV) of the group 3 cluster (EMCV-3) was first reported in 2002 to be responsible for the deaths of orang-utans in an outbreak in the Singapore Zoo. After this first outbreak, sporadic infections among the primate population caused by EMCV-3 continued to be reported, suggesting that the virus remains prevalent in Singapore. To prevent future infections, we constructed an experimental vaccine using binary ethylenimine (BE) to inactivate the EMCV-3 virus. The immunological performance of the BE-inactivated (BEI) virus was analysed in mice and the neutralising titre of the immune sera measured against the wild-type EMCV-3. The BEI virus showed a strong immunological response in BALB/c mice at 1: 40,960 titre, suggesting that it can be used as a promising experimental vaccine candidate to prevent EMCV-3 infections.

show abstract

Development and serology based efficacy assessment of a trivalent foot-and-mouth disease vaccine

Cited by 9 publications

References 28 publications

Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A

Immuno-Efficacy of Multi-Epitope Chimeric Peptides Against Foot and Mouth Disease Virus: Potential Vaccine Candidates for Newly Emerged Serotype O and A

Emergence of a novel sublineage, MYMBD21 under SA-2018 lineage of Foot-and-Mouth Disease Virus serotype O in Bangladesh

Evaluation of a BE-inactivated whole virus preparation using an encephalomyocarditis virus strain that was isolated from fatal infection in orangutans

Contact Info

Product

Resources

About